Elvina Almuradova/LinkedIn
Feb 28, 2025, 14:50
Elvina Almuradova: The FDA has granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive mCRPC
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on LinkedIn:
“The FDA has granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive mCRPC after ARPI, based on promising phase 1/2a SECuRE trial data.
- No dose-limiting toxicities in 15 patients.
- 73% had PSA reductions, with 45% showing >50% decline after a single dose.
- Mild side effects, most commonly dry mouth (33%).
This could be a game-changer in PSMA-targeted radiotherapy, offering an alternative to 177Lu-based treatments.
Looking forward to further developments!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 30, 2025, 16:03
Mar 30, 2025, 15:52
Mar 30, 2025, 15:48
Mar 30, 2025, 15:37
Mar 30, 2025, 15:24